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Abstract
Background: Observational studies have recently associated a decrease in serum parathyroid hormone (PTH) level
with a higher rate of mortality among hemodialysis (HD) patients. Decreases in PTH level can result from medical
intervention (MPD) and surgical parathyroidectomy (PTX), or may occur spontaneously, usually associated with an
underlying malnutrition-inflammation syndrome (SPD). The aim of our study was to prospectively identify the
incidence of decreases in PTH level in a cohort of HD patients and the frequency distribution of the different
causes (MPD, PTX and SPD), as well as to evaluate the survival outcomes for each PTH group (MPD, PTX and SPD)
compared to patients who did not experience a PTH decrease over the first 36 months of the study (NPD).
Methods: The 197 patients receiving HD at our center in January 2010, and meeting our eligibility criteria, were
enrolled in our prospective study, and were observed for a period of 60 months. A decrease in PTH level >50 %
between two successive PTH measurements obtained within an interval <3 months was defined as a significant
event. MPD referred to a decrease in PTH due to an increased oral calcium intake, increased dialysate calcium
concentration (DCC), increased alfacalcidol use, or use of cinacalcet therapy. A surgical 7/8 PTX was performed in
young patients or in patients in whom cinacalcet therapy failed. SPD referred to a decrease in PTH related to a
medical or surgical event. Baseline characteristics among patients in each group (MPD, PTX, SPD, and NPD) were
evaluated using Fisher’s exact test. The 60-month survival was evaluated using Kaplan-Meier and Cox multivariable
proportional hazards models. Univariate and multivariate Cox analyzes were used identify variables with mortality.
The relative risk of mortality was expressed as a hazard ratio (HR).
Results: The distribution of the 197 patients forming our four study groups was 34 % in the NPD group, 35 % in
the SPD group, 25 % in the MSD group and 6 % in the PTX group. Among patients in the SPD group, the main
acute comorbid conditions were peripheral vascular and cardiac complications, sepsis, fractures, and cancers with
an increase in serum CRP level (from 14.3 ± 18 to 132 ± 90 mg/L) and a decrease in serum albumin (from 33 ± 4.5
to 28.6 ± 4 g/L). In the MPD group, the main therapeutic change was an increase in DCC, either independently or in
association with cinacalcet therapy. The median survival rate among patients was 10 months for SPD, compared to
22 months among patients in the MPD group (p < 0.001). Using multivariable Cox model and taking the NPD group as
reference, the risk of mortality was lower among patients in the MPD group (HR, 0.42[0.2-0.87] p = 0.01), with survival
being comparable for the SPD and NPD groups (HR, 1.3 [0.75-2.2]). No mortality was observed in the PTX group.
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Conclusion: The poor outcomes associated with SPD, related to acute comorbid conditions, should not lead to
undertreat secondary hyperparathyroidism whose appropriate medical or surgical therapies are associated with better
outcomes.
Keywords: Parathyroid hormone, Survival rate, Haemodialysis, Parathyroidectomy, Calcium, Vitamin D, Calcimimetics
Background
Secondary hyperparathyroidism (SHPT) is a common
comorbidity in patients with chronic kidney disease
(CKD) and, particularly in those on hemodialysis (HD) [1].
Due to an unpredictable bone resistance to parathyroid
hormone (PTH) action, maintaining a mild biological
SHPT is recommended in most HD patients to favor a
normal bone turnover rate. According to the most recent
international Kidney Disease Improving Global Outcomes
guidelines, experts recommend target serum PTH levels of
2 to 9 times the upper normal limit of the assay in HD pa-
tients [2]. Identification of bone turnover rate from serum
PTH levels, however, is not straightforward. Bone histology
studies have shown that SHPT can be excluded by lower
serum PTH levels and adynamic bone disease (ABD) by
higher serum PTH levels [3]. Between these two limits ex-
ists a ‘grey zone’ in which normal bone, ABD and SHPT
can all be observed. Therefore, the assessment of serum
bone markers and even bone biopsies, at times, are neces-
sary to better assess the rate of bone turnover in HD
patients.
Besides, the KDIGO experts suggest that “marked
changes in PTH levels in either direction within the tar-
get range prompt an initiation or change in therapy to
avoid progression to levels outside of this range (2C)”[2].
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) provided evidence of an increase in mean
serum PTH level being an important health issue in HD
patients [4].
Beyond having consequences on the rate of bone turn-
over, elevated PTH is also a well-known uremic toxin
which has been associated with cardiovascular calcification
[5] and mortality [4]. However, it is important to note that
both low [6] and high [7] serum PTH levels have been asso-
ciated with poor health outcomes in HD patients. While
low PTH levels commonly result from surgical parathyroid-
ectomy (PTX) and the prescription of calcimimetics, vari-
ous other causes can result in low PTH levels, including an
excessive calcium and vitamin D load and hypercalcemia
[8, 9], as well as the malnutrition-inflammation syndrome
[10–13] and prolonged immobilization [14].
Recently, two observational studies have reported an
increased rate of mortality associated with low PTH
levels [15, 16]. However, as these two studies failed to
identify the underlying cause of low PTH levels, we be-
lieve that their suggestion of a possible risk in treating
SHPT in HD patients might be misleading. To address
this issue, we undertook our study to prospectively
identify the incidence of PTH decrease in a cohort of
HD patients and to describe the frequency distribu-
tion of the different causes of decreased PTH in this
clinical cohort. A second aim of our study was to
evaluate survival outcomes associated with different
identified causes of decreased PTH and in patients
with no PTH decrease throughout their course of
treatment.
Methods
All patients on HD at our institution in January 2010
were screened for eligibility using the following exclu-
sion criteria: dialysis vintage <6 months and previous
surgical parathyroidectomy (PTX). Patients meeting our
eligibility criteria were enrolled into the study and ob-
served for a period of 60 months. The study was con-
ducted in compliance with the Declaration of Helsinki,
and all patients provided their signed consent to have
their data entered in a database for analysis.
The pre-dialysis, mid-week, serum PTH level was sam-
pled every month. For analysis, patients were classified
by the presence or absence of an event of significant de-
crease in serum PTH level over the first 36 months of
the study. A significant decrease in serum PTH level was
defined as a decrease of more than 50 % between two
measurement periods within an interval of less than
3 months, with the mean of two successive PTH values
used to calculate the change in PTH (Fig. 1). This was
based on the study from Cavalier et al. reporting that at
least 40 % difference between PTH measurements is re-
quired from their intraindividual variability study [17].
A surgical PTH decrease was defined as a decrease in
serum PTH level identified after surgical subtotal (7/8)
parathyroidectomy (PTX). A medical PTH decrease
(MPD) was defined as a decrease in serum PTH level as-
sociated with the use of one or more treatments known
to decrease PTH, including: native vitamin D supple-
mentation; prescription of calcitriol, or of its analogs,
oral calcium, and cinacalcet; and increased dialysate cal-
cium concentration (DCC). A spontaneous PTH decrease
(SPD) was defined as a decrease in serum PTH level
without any change in therapy. The underlying clinical
condition was recorded together with serum levels of al-
bumin and C-reactive protein (CRP). Patients with no
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identified decrease in PTH were classified in the no PTH
decrease (NPD) group.
Patients were dialyzed thrice-weekly, 4 to 8-h per ses-
sion, using polysulfone high-flux filters (FX 60, 80, 100,
800 and 1000; Fresenius Medical Care©, Bad Homburg,
Germany) in HD or post-dilution online hemodiafiltra-
tion (HDF). Blood flow rate ranged from 220 to 400 ml/
min, and the dialysate flow rate ranged from 350 to
800 ml/min. The standard dialysis calcium concentration
was 1.5 mmol/L. However, a 1.25 mmol/L concentration
was prescribed for patients with low PTH levels
(<100 pg/mL), and a 1.75 mmol/L concentration was
recommended in cases where the PTH levels were high
(>400 pg/mL). Our strategy to optimize mineral and
bone status during HD has been previously reported
[18], and has remained stable for years.
The rate of bone turnover was assessed using the bone
markers: bone alkaline phosphatase (b-ALP) and
Beta(ß)-crossLaps (CTX). The prevention and treatment
of SHPT included systematic cholecalciferol supplemen-
tation (100 000 U/month), individualization of DCC [19]
and oral calcium or oral alfacalcidol therapy; cinacalcet
was introduced as a last alternative. PTH lowering ther-
apies were decreased for patients with acute comorbidi-
ties and SPD. Surgical 7/8 PTX was performed in
patients for whom conservative therapy failed.
The following patient information was recorded: med-
ical history, including cardiovascular events and risk fac-
tors; pharmaceutical treatment, including the use of
statins, warfarin, vitamin D, cinacalcet, and phosphate
binders; and baseline results from standard serum levels
laboratory tests. Serum levels were sampled were ob-
tained on a monthly basis for the measurements of:
PTH, determined using a second-generation assay (Elec-
SysG; Roche© Diagnostics, Meylan, France, reference
values 10–65 pg/mL), calcium, phosphorus, albumin,
and CRP. The rate of bone turnover was evaluated every
6 months using serum levels of bone alkaline phosphatase
(b-ALP; chemiluminescence, Beckman© Access, reference
values 3.7–20 μg/L), ß-CrossLaps (CTX; Elecsys, Roche©
Diagnostics, Meylan, France) and 25-OHD (Abbott© La-
boratories. Abbott Park, Illinois, U.S.A.). For laboratory
tests, blood samples were obtained in a non-fasting state
before a mid-week dialysis session, with all serum levels
measured from the same blood draw. Single pool Kt/V
was calculated using the second-generation logarithmic
formula of Daugirdas. Daily protein intake was measured
by calculating normalized protein nitrogen appearance
(nPNA). Common laboratory analyses were performed
by the Grand Vallon Laboratory (NOVESCIA© Lyon,
France).
Statistical analysis
The data of patients who experienced more than one
episode of PTH decrease were excluded from the ana-
lysis. The mean ± standard deviation (SD) was calculated
for all variables. Baseline characteristics among patients
in each group (MPD, PTX, SPD, and NPD) were evaluated
using Fisher’s exact test, with a regression correlation ap-
plied when necessary.
The 60-month survival was analyzed using Kaplan-
Meier and Cox multivariable proportional hazards
models. Univariate analysis was used to identify variables
associated with all-cause mortality. All identified vari-
ables were included in a multivariate Cox analysis, using
a backward elimination to identify independent factors
associated with mortality, using a p <0.05 to retain a
variable. The relative risk of mortality was expressed as a
hazard ratio (HR).
Data were censored for kidney transplantation, trans-
fer to another dialysis center or lost to follow-up, and at
the end of follow-up. All statistical analyses were per-
formed using MedCalc software version 11.5.1.0 (MedCalc
Software, Ostend, Belgium). A p value ≤0.05 was consid-
ered significant in all analyzes.
Results
Among the 235 patients receiving HD in January 2010,
21 were excluded for dialysis vintage <6 months and 10
for previous PTX. The data of another seven patients
were excluded at the end of the study due to more than
one episode of PTH decrease. The distribution of the
197 remaining patients among the four causative groups
of a PTH decrease (NPD, SPD, MPD, and PTX) is
shown in Fig. 2 and summarized as follows: NPD, 34 %
(n = 67); SPD, 35 % (n = 70); MPD, 25 % (n = 50); and
PTX, 6 % (n = 10). Baseline characteristics of patients
among the four groups are reported in Table 1. The
characteristics of patients requiring PTX during the
study period were quite different from those of patients
in the other groups. Namely, patients in the PTX group
were younger and had a lower prevalence of cardiovascular
Fig. 1 Protocol design
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disease, diabetes, and malnutrition-inflammation syndrome,
but with higher baseline serum PTH levels and DCC, as
well as a more frequent use of alfacalcidol and cinacalcet.
Compared to patients in the SPD and NPD group, patients
in the MPD group had started HD more recently (i.e.,
shorter dialysis vintage) and had a lower prevalence of car-
diovascular disease and diabetes. Specific comparison of
baseline characteristics among patients in the SPD and
MPD groups is reported in Table 2. Compared to patients
in the MPD group, patients in the SPD group showed lower
serum PTH and albumin levels, lower DCC and higher
CRP levels. The median serum PTH value decrease was
−75 % in the SPD group and −70 % in the MPD group.
After the initial serum PTH value decrease, PTH level
remained stable after 6 months in the MPD group, but
tended to increase in the surviving SPD patients. This
could be due to therapeutic adjustments or acute co-
morbidity improvement. No significant serum PTH level
increase was observed using the same criteria (>50 %
from baseline in less than 3 months) in the NPD group.
The overall mortality rate among patients in the SPD
group was 73 %, compared to a rate of 24 % among
patients in the MPD group (p < 0.001), with a median
survival time of 10 months for the SPD group and
24 months for the MPD group (p < 0.001).
The comorbid conditions and therapeutic changes as-
sociated with a decrease in PTH in the SPD and the
MPD groups are reported in Tables 3 and 4, respectively.
Among patients in the SPD group, the main acute co-
morbid conditions were peripheral vascular and cardiac
complications, sepsis, fractures, and cancers with an
increase in serum CRP level (from 14.3 ± 18 to 132 ±
90 mg/L) and a decrease in serum albumin (from 33
± 4.5 to 28.6 ± 4 g/L). In the MPD group, the main
therapeutic change associated with a decrease in PTH
was an increase in DCC, either independently or in
association with cinacalcet therapy, and less fre-
quently associated with the prescription of oral cal-
cium or alfacalcidol.
The Kaplan-Meier univariate survival analysis is sum-
marized in Fig. 3. Data from the PTX group was not in-
cluded in the analysis due to the limited number of
patients in this group, with no incidence of death over
the study period. The rate of mortality was higher
among patients in the SPD group than among patients
in the MPD group (p < 0.001), with a HR of 3.5 (range,
2–6) for the SPD group and a HR of 1.36 (range, 0.8–
2.3) for the MPD group. Moreover, the mortality rate
among patients in the MPD group was lower than the
rate among patients in the NPD group (HR, 0.38; range,
0.22–0.66; p < 0.001). Using a multivariate Cox model,
the mortality rate among patients in the MPD group
remained significantly lower than the rate among patients
in the NPD group (HR, 0.42; range, 0.2–0.87; p = 0.01) or
the SPD group (HR, 0.36; range, 0.18–0.73; p = 0.004),
after adjustment for age, dialysis vintage, peripheral vascu-
lar disease, stroke, diabetes, cardiac disease, serum albu-
min, central venous catheter and warfarin use. The HR of
mortality, for both the univariate and multivariate Cox
model, are shown in Fig. 4.
Fig. 2 Relative frequency of patients in the 4 groups. 0 = no PTH decrease. Spontaneous = Spontaneous PTH decrease. Medical = medical PTH
decrease. PTX = PTX patients
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Table 1 Baseline characteristics
No PTH decrease N = 67 Spontaneous PTH decrease N = 70 Medical PTH decrease N = 50 Surgical PTX N = 10
Age (years) 66.8 ± 14 71.2 ± 12 64.1 ± 16 51 ± 15 *
Female gender (%) 46.3 27.1 * 53.1 40
Dialysis vintage (months) 75.1 ± 98 71.5 ± 73 53 ± 61 * 90.5 ± 94
Diabetes (%) 37.3 41.4 24.5 * 0 *
Cardiac disease (%) 28.4 30 10 * 10 *
Peripheral vascular disease (%) 27 25 8 * 0 *
Stroke (%) 9 13 4 * 0 *
Cancer (%) 7 16 16.3 10
BMI (kg/m2) 25.8 ± 5 24.7 ± 5 24.6 ± 4 25 ± 4
Body weight (kg) 71.1 ± 18 69.7 ± 16 67.4 ± 13 70.5 ± 17
Dialysis session time (min) 330 ± 95 322 ± 90 327 ± 92 410 ± 100 *
Central catheter (%) 13.4 20 12.5 10
HDF (%) 40.3 40.3 39.6 12.5 *
Dialysate calcium (mmol/L) 1.5 ± 0.16 1.47 ± 0.16 1.53 ± 0.14 1.7 ± 0.18 *
spKt/V 2.3 ± 0.7 2.1 ± 0.6 2.4 ± 0.7 2.7 ± 1 *
nPNA (g/kg/day) 1.42 ± 0.6 1.14 ± 0.2 1.3 ± 0.4 1.43 ± 0.3
PTH (pg/mL) 198.6 ± 152 218 ± 126 280 ± 144 498 ± 315 *
Calcaemia (mmol/L) 2.26 ± 0.14 2.23 ± 0.14 2.25 ± 0.12 2.31 ± 0.12
Phosphataemia (mmol/L) 1.42 ± 0.3 1.34 ± 0.36 1.36 ± 0.3 1.26 ± 0.2
b-ALP (μg/L) 18 ± 10 21 ± 15 19 ± 11 35.6 ± 27 *
25-OHD (nmol/L) 106 ± 49 112 ± 39 104 ± 41 120 ± 28
Serum Albumin (g/L) 33.5 ± 4 31.1 ± 4 33.8 ± 4 36.8 ± 3 *
C-reactive protein (mg/L) 11.7 ± 16 14.6 ± 18 7.6 ± 8 4.3 ± 3 *
Cholecalciferol (%) 90.5 92.3 93.3 90
Alfacalcidol % (μg/week) 10 (2.2) 10 (1.6) 25 (2.5) 50 (2.9) *
CacCO3 % (g/day) 27 (1.2) 16 (1.1) 30 (2) 30 (2.4)
Sevelamer % (g/day) 39 (1.8) 21 (1.2) 37 (1.8) 20 (2)
Cinacalcet % (mg/day) 22 (35) 7 (30) 6 (39) 50 (60) *
*P < 0.05; **P < 0.005 with at least one other value
Table 2 Comparison between spontaneous PTH decrease (SPD) and medical PTH decrease (MPD) groups
SPD MPD
T-1 T-2 T-1 T-2
PTH pg/mL median (95 % CI) 330 (125 – 785) 80 (10 – 200)** 490 (190 – 1230) 147 (122 – 178) **
Calcaemia mmol/L 2.22 ± 0.15 2.2 ± 0.12 2.35 ± 0.18 2.24 ± 0.13 *
Phosphataemia mmol/L 1.38 ± 0.4 1.21 ± 0.4 * 1.45 ± 0.4 1.35 ± 0.4 *
Serum albumin g/L 33 ± 4.5 28.6 ± 4 ** 34 ± 4 34.2 ± 4.3
CRP mg/L median (95 % CI) 8.1 (8 – 50) 105 (15 – 300) ** 3,6 (0 – 25) 4,5 (0 – 29)
Dialysate calcium mmol/L 1.51 ± 0.17 1.35 ± 0.2 * 1.52 ± 0.18 1.65 ± 0.15 *
Mortality 73 % 24 %
Median survival time 10 months 24 months
* P < 0.05; ** P < 0.005 between T-1 and T-2
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Discussion
To our knowledge, this is the first study to stratify HD
patients according to their underlying causes of de-
creases in serum PTH levels in patients on HD, and the
resultant effects of decreases in PTH levels on the sur-
vival outcomes of these patients. Among the 197 HD pa-
tients forming our study group, a decrease in PTH level
was associated to an acute comorbid condition in one-
third of patients (SPD group) and to a change in medical
therapy (MPD group) or PTX in another one-third of
patients. Survival over the 60-month period of the study
was lower among patients in the NPD and SPD groups,
compared to the survival rate among patients in the
MPD and PTX groups. Even after adjustment for pos-
sible influencing variables, the prognosis remained dra-
matically lower among patients in the NPD and SPD
groups.
Regulation of PTH
SHPT is normally observed in patients with CKD stage
4 to 5, resulting from a prolonged decrease in serum
levels of calcium and vitamin D (1,25(OH)2D3) or an in-
crease in serum phosphate level. SHPT in this clinical
population has been associated to an increase in PTH
gene expression, synthesis, and secretion, and to a prolif-
eration of parathyroid cells in chronic cases [20]. More
recently, the role of Klotho deficiency, resistance of para-
thyroid cells to fibroblast growth factor (FGF)-23 action,
due to a decrease of fibroblast growth factor receptor 1
expression [21], and a decrease of serum 1,25(OH)2D3
due to the excess FGF-23 synthesis, have been postulated
to influence SHPT in patients with end-stage CKD [22].
Tertiary hyperparathyroidism, with an increase of the
set-point calcium-PTH and frequent hypercalcemia, repre-
sents the response of the autonomous function of one or
more parathyroid glands to long-standing SHPT [23]. The
consequences of prolonged SHPT include bone disease,
previously known as osteitis fibrosa, with an increased risk
for radiological demineralization [24], fractures [25] and
brown tumors [26], as well as an increased risk for cardio-
vascular calcification [5] and mortality [2].
High PTH-related morbidity and mortality
In a recent metaanalysis of HD patients, Natoli et al. re-
ported that only a high serum PTH level was associated
with mortality [27]. Using the Fresenius US database,
Block et al. reported an increased rate of mortality only
among patients with a serum PTH level >600 pg/mL in
an adjusted model, whereas in an unadjusted model,
only low PTH levels were associated with a higher rate
of mortality [11]. The same findings were confirmed for
patients with CKD not on dialysis by Kovesdy et al. [7]
and Nakai et al. in Japan [28]. The mechanism of PTH
toxicity is poorly understood. However, an elevated cal-
cium x phosphorus (Ca x P) product associated with ter-
tiary HPT and a high serum PTH level, associated with
high serum FGF-23level, have been associated with a risk
for progression of cardiovascular calcification [5, 29].
Low PTH-related mortality
In patients with CKD and in those on HD in particular,
both low and high serum PTH levels have been associ-
ated with a higher rate of mortality [30]. Twenty years
ago, Fournier et al. reported that a persistently low PTH
state could result from aluminum intoxication, older
age, diabetes, and excessive calcium and vitamin D use,
as well as being frequently observed in patients undergo-
ing peritoneal dialysis [31, 32]. The toxicity of a serum
level of PTH that is within normal range, and even
judged to be too low in HD patients, is probably related
to an underlying condition, such as hypo phosphatemia
and poor nutrition [33]. Over the last century, the exces-
sive use of calcium and vitamin D to treat hyperpho-
sphatemia and prevent SHPT has led to iatrogenic ABD,
with the resulting hypercalcemia increasing the risk of
extraosseous calcifications and mortality [8, 34]. Based on
the data in the Taiwan HD registry, Lin et al. found that a
low serum PTH level increased the risk of mortality usu-
ally when associated with hypercalcemia [35]. Today, in
industrialized countries, non-calcium phosphate binders
Table 3 Comorbid conditions associated with spontaneous PTH
decrease (SPD)
SPD
N = 68 (35 %)
Peripheral vascular disease-arterial by-pass-amputation (n = 15)
Severe sepsis (n = 10)
Factures (n = 10)
Osteoarthritis (n = 10)
Cancer (n = 7)
Cachexia (n = 4)
Gut infection (n = 4)
Cardiac disease (n = 3)
Postoperative (n = 3)
Stroke (n = 2)
Table 4 Changes in treatments associated with medical PTH
decrease (MPD)
MPD
N = 50 (25.5 %)
↑ CCD 1.5 to 1.75 mmol/L (n = 25)
↑ CCD from 1.25 to 1.5 mmol/L (n = 4)
↑CCD from 1.5 to 1.75 mmol/L + Cinacalcet (n = 10)
Oral calcium (n = 6)
Alfacalcidol (n = 5)
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and higher serum PTH targets are used to prevent an
excessive calcium load and hypercalcemia and, therefore,
iatrogenic ABD is infrequently reported [4].
In addition to iatrogenic causes of low serum PTH,
Fukagawa et al. suggested that a low serum PTH level
may reflect a malnutrition status, which would explain
the poor prognosis of these patients [36]. In HD pa-
tients, Mehrotra et al. reported an inverse relationship
between age and serum levels of PTH [37], with a
further association between low serum albumin levels
and low PTH level in a Japanese cohort of HD patients
[38]. The malnutrition-inflammation syndrome was
associated with low PTH levels and poor outcomes
[10, 39]. In their study of 748 HD patients, Dukkipati et
al. also reported that low PTH (<150 mg/mL) was
associated with protein energy wasting and inflamma-
tion. They further reported that a PTH level between
100 and 150 pg/mL to be associated with a greater sur-
vival compared to other PTH levels [40].
The effect of inflammation of PTH levels was
described by Bologa et al. who reported that, in vitro,
PTH secretion is suppressed by IL-6 [41], with IL-1ß
Fig. 3 Survival curve (Kaplan-Meier) comparing patients of the 4 groups
Fig. 4 Hazard Ratio of mortality according to the PTH decrease groups. No decrease group as reference.———— Univariate. ____ Multivariate Cox
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inhibiting PTH secretion in parathyroid tissue slices
[42], with IL-1 specific receptors upregulating the
calcium-sensing receptor mRNA. Therefore, the KDIGO
experts recommend maintaining serum PTH levels in a
large range, from to 2–9 times the upper limit of the
assay in HD patients to lower the risk of severe osteitis
fibrosa and ABD [2] and to favor survival, based on the
U-shape survival curve associated with serum PTH level.
Hence, it is advisable to treat SHPT in HD patients in
order to prevent health complications related to SHPT
and improve survival, but without surpassing target
levels due to the risk of ABD and related hypercalcemia.
Treatment for SHPT
Available treatments for SHPT include the use of native
vitamin D [43], oral calcium [44], high DCC [19], calci-
triol and analogs [45], and cinacalcet [46], as well as
surgical PTX [47]. In a randomized controlled study
evaluating the relative effectiveness of using calcium salt
and non-calcium phosphate binders in the treatment of
SHPT, outcomes were frequently worse for patients re-
ceiving calcium salts due to an inadequate calcium load,
resulting in higher calcemia and more frequent episodes
of hypercalcemia and extraosseous calcification [48]. By
comparison, observational studies have described the
use of oral calcium to be associated with better out-
comes when prescribed adequately [49, 50]. The out-
comes associated with the use of DCC are difficult to
evaluate as few centers adjust DDC to levels of calcemia
and bone turnover markers in patient-specific ways as
we do in our center [19]. However, an observational
study in a French regional cohort of HD patients identi-
fied no deleterious effects of high DCC (1.75 mmol/L)
when prescribed for patients with hypo- or normo-
calcemia [51].
A large observational study based in the United States
(US) identified the use of calcitriol, and of its analogs, as
being effective in lowering the risk of mortality in HD
patients [52], as we previously reported in our regional
cohort [53]. Randomized trials did not provide evidence
of a survival advantage with the use of cinacalcet therap-
ies, compared to high doses of calcitriol, or of its analogs
[54]. In secondary analyzes of the data from this trial,
cinacalcet therapies were associated with a lower inci-
dence of fractures [55] and calciphylaxis [56]. The long-
term prognosis of cinacalcet therapies, compared to
PTX, has yet to be evaluated. In our study, we reported
better outcomes among patients in the MPD group than
among those in the NPD and SPD groups who were
using calcium therapy (DCC and oral calcium), cinacal-
cet and alfacalcidol. When calcium, vitamin D or cina-
calcet are used to lower serum levels of PTH, it is not
possible to differentiate the impact of these therapies on
survival from the impact of changes in serum levels of
vitamin D or the Ca x P product on survival.
Low PTH levels after surgical PTX has been reported
to improve outcomes in a US-based study of HD pa-
tients [57]. However, Konstantidinis et al. recently re-
ported that only a few patients meeting the biological
criteria for PTX actually accepted the surgery in the US,
even if the PTX allowed achieving biological KDOQI
targets of PTH [58]. In Japan, the survival rate after PTX
has been reported to be very good, with an early mortal-
ity rate of only 0.15 % [59]. In our study, patients who
underwent surgical PTX had excellent mid-term out-
comes; however, the majority of these patients under-
went kidney transplantation by the end of the study
period and, therefore, the longer term survival could not
be evaluated.
Causes and impact of a decreased PTH level
In a French observational study, using the KDIGO bio-
logical target of PTH level, Merle et al. reported that a
decrease in serum PTH level after one year, including
both changes from normal to low levels and from high-
to-low levels, was associated with a higher rate of
cardiovascular-related mortality [16]. Among factors as-
sociated with a higher risk of mortality, Merle et al.
identified a high serum CRP level and a high DCC
(1.75 mmol/L). Of importance is their finding that mor-
tality risk increased when high DCC and a low albumin
level were associated with a PTH decrease; high DDC
was not associated with an increased rate of mortality
among patients in whom PTH level remained in the low
range. However, Merle et al.’s study was based only on
biannual PTH sampling, and information on acute co-
morbid conditions or changes in therapeutic interven-
tion was not available between sampling periods.
Moreover, high DCC was prescribed in their study based
on usual care rather than being individualized based on
PTH values. We consider that using the KDIGO target
level (i.e., low-normal-high level classification) to study
PTH variations may be questionable as a small variation
in PTH level could be associated with a change in target
zone classification. In the COSMOS study of 4500
European HD patients evaluated at 6-month intervals,
Fernandez-Martin et al. reported that a serum PTH
decrease was not associated with an increased rate of
mortality when baseline PTH levels were within the
KDIGO range of normal (168 – 674 pg/mL), with the
risk of mortality significantly increasing among patient
with a baseline PTH level <168 pg/mL [15]. Again, no
data on acute comorbid conditions or change in thera-
peutic intervention was provided. We hypothesize that a
decrease in PTH among patients in the low level
KDIGO range would reflect an acute comorbid condi-
tion, rather than a medical decision on treatment, which
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would explain the finding of a higher rate of mortality.
In their large US-based cohort study of HD patients,
Streja et al. reported that an increased in serum PTH
level from <150 pg/mL to 150–300 pg/mL was associ-
ated with a lower risk of mortality [60]. Once again, this
was an observational study with no information on the
underlying cause of variation in PTH level provided.
Limitations
The fact that we conducted a monocentric study with a
small number of patients limits the generalization of our
results. However, the treatment using a strategy that has
been homogenous for 20 years, as well as using monthly
serum PTH sampling, allowed us to identify factors as-
sociated with variation in serum PTH levels.
Conclusion
In our study, we determined the survival outcomes asso-
ciated with different causes of a decrease in PTH level in
HD patients. A SPD, resulting from an acute comorbid
condition, is associated with poor survival outcomes,
with MPD and PTX being associated with lower rates of
mortality. The poor outcomes associated with SPD
should not lead to underestimate the risk of SHPT that
is highly prevalent in HD patients. Medical or surgical
therapy should be implemented in order to prevent a
negative impact of SHPT on bone and vascular health.
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